About Lykos
Lykos is a company based in San Jose (United States) founded in 2014. Lykos has raised $315.1 million across 2 funding rounds from investors including Helena, Steveandalex and Vine Ventures. Lykos offers products and services including Midomafetamine Capsules. Lykos operates in a competitive market with competitors including GH Research, Small Pharma and Ketabon, among others.
- Headquarter San Jose, United States
-
Sectors
Government & Social SectorHealthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$315.1 M (USD)
in 2 rounds
-
Latest Funding Round
$100 M (USD), Series A
Jan 05, 2024
-
Investors
Helena
& 7 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Lykos
Lykos offers a comprehensive portfolio of products and services, including Midomafetamine Capsules.
Investigational treatment for PTSD using psychedelic compounds
Funding Insights of Lykos
Lykos has successfully raised a total of $315.1M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $100 million completed in January 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Lykos
Lykos has secured backing from 8 investors, including institutional and venture fund investors. Prominent investors backing the company include Helena, Steveandalex and Vine Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments are directed toward early-stage technology companies.
|
Locked | Locked | Locked | |
|
Venture capital firm supporting AI founders through investments and community.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Lykos
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Lykos
Investment portfolio details for Lykos
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Lykos
Detailed financials for Lykos
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Lykos Comparisons
Peer comparison for Lykos
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Lykos
Lykos operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GH Research, Small Pharma and Ketabon, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for mental disease management are developed using 5-MeO-DMT formulations.
|
|
| Locked | Locked | Locked |
Psychedelic-based therapeutics for mental health conditions are developed.
|
|
| Locked | Locked | Locked |
Develops innovative therapeutics for treatment-resistant depression.
|
Detailed competitors of Lykos
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Lykos
Complete news archive for Lykos
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Lykos
Lykos was founded in 2014 and raised its 1st funding round 9 years after it was founded.
Lykos is headquartered in San Jose, United States. It is registered at San Jose, California, United States.
Amy Emerson is the current CEO of Lykos.
Lykos is a funded company, having raised a total of $315.1M across 2 funding rounds to date.
Founded in 2014 and based in San Jose, United States, Lykos operates in the biotechnology sector focused on mental health treatments. Therapeutics are developed to address conditions such as post-traumatic stress disorder through a combination of MDMA capsules, psychological interventions, and supportive services. Operations emphasize clinical development and integration of pharmacological and therapeutic approaches for patient care.
Lykos's top competitors include GH Research, Small Pharma and Ketabon.
Lykos offers Midomafetamine Capsules.
Lykos has 8 investors. Key investors include Helena, Steveandalex, Vine Ventures, True Ventures, and Unlikely Collaborators Foundation.